Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus with minimal steroids plus daclizumab versus mycophenolate mofetil in primary liver transplantation
2004-001617-34Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2004
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in hepatic disease (2 arms), sponsored by Astellas Pharma. Primary endpoint: Biopsy-proven acute rejection requiring treatment within 3 months. Started Sep 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
hepatic disease
Beyond the preview
Go deeper on 2004-001617-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001617-34.